Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model (scientific article published on 14 April 2016)

Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease

Q30665466

Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment

Q33796155

Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility

Q33904964

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies

Q33910280

Gene-gene interactions in breast cancer susceptibility

Q34017597

Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study

Q74157664

Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families

Q84785212

Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel

Q85247141

Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consorti

Q86554647

Multigene panel testing: planning the next generation of research studies in clinical cancer genetics

Q87968246

Incorporating tumour pathology information into breast cancer risk prediction algorithms

Q34048046

Breast-cancer risk in families with mutations in PALB2

Q34148873

Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2

Q34384153

Cancer risks and mortality in heterozygous ATM mutation carriers

Q34422846

ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles

Q34546389

CHEK2 is a multiorgan cancer susceptibility gene

Q34551970

The T/G 13915 variant upstream of the lactase gene (LCT) is the founder allele of lactase persistence in an urban Saudi population

Q34697321

No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families

Q35033167

Development of cancer genetic services in the UK: A national consultation

Q35124732

Rare variants in the ATM gene and risk of breast cancer

Q35608690

Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry

Q35609710

The genetic epidemiology of breast cancer genes

Q35959353

Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

Q35996692

Gene-panel sequencing and the prediction of breast-cancer risk

Q36175072

Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study

Q36300580

CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer

Q36449203

Prediction of breast cancer risk based on profiling with common genetic variants

Q36583004

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

Q36615665

Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening

Q37004478

A prospective study of breast cancer risk in relatives of BRCA1/BRCA2 mutation carriers

Q37004562

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls

Q37048943

PALB2 and breast cancer: ready for clinical translation!

Q37074279

Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls

Q37307305

Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer

Q37373918

BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface

Q37507410

A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact

Q37632049

Hereditary breast cancer: the era of new susceptibility genes

Q39657506

Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis

Q41748948

Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.

Q46520947

CHEK2 variant I157T may be associated with increased breast cancer risk

Q47236534

Loss-of-function variants in ATM confer risk of gastric cancer

Q48168326

A breast cancer prediction model incorporating familial and personal risk factors.

Q52000310

Programs for pedigree analysis: Mendel, Fisher, and dGene

Q59760870

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

breast cancer

Q128581

P304

page(s)

1190-1198

P577

publication date

2016-04-14

P1433

published in

Genetics in Medicine

Q15765508

P1476

title

Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model

P478

volume

Reverse relations

cites work (P2860)

Q93103805	A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density
Q92102602	Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool
Q91045517	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors
Q87909686	Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening
Q30238753	Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
Q39263736	Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
Q92846998	Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers
Q91211233	Cancer genetics, precision prevention and a call to action
Q52672618	Clinicians' use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey.
Q52584688	Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group.
Q90109747	Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study
Q90748460	Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine
Q112287480	Identification of Novel CircRNA-miRNA-mRNA Regulatory Network and Its Prognostic Prediction in Breast Cancer
Q89748385	Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer
Q38739022	Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
Q37524981	Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies
Q90744442	Risk Models for Breast Cancer and Their Validation
Q54950358	Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data.
Q100402781	Statistical approaches for meta-analysis of genetic mutation prevalence
Q49356370	The use of panel testing in familial breast and ovarian cancer.
Q38721663	Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries

P356	DOI	10.1038/GIM.2016.31
P2888	exact match	https://scigraph.springernature.com/pub.10.1038/gim.2016.31
P932	PMC publication ID	5086091
P698	PubMed publication ID	27464310